Philippe Gallay

Scientific Advisor at Abliva AB

Philippe Gallay

Philippe Gallay

Scientific Advisor at Abliva AB

Biography

Philippe Gallay, Ph.D.
Scientific Advisory Board

Dr. Gallay is Professor, Department of Immunology and Microbial Science at the Scripps Research Institute in La Jolla (San Diego), California. Dr. Gallay holds a Swiss Federal Diploma (MS), from the Institute of Biochemistry, Epalinges, Switzerland and a PhD from Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Dr. Gallay’s research program examines the molecular basis of HIV, HCV, and HBV pathogenesis, including characterization of host proteins modulating viral replication, such as various cyclophilins (Host Targeting Antivirals). In particular, Dr. Gallay has studied the role of cyclophilin inhibition on disease progression, and has investigated cyclophilin-NS5A complexes, viral mutations, and synergism with other antiviral compounds, including the Direct Acting Antivirals. Dr. Gallay has presented his research at numerous scientific and research symposia worldwide. He serves as a reviewer for more than 40 journals, has served as a Member on the Center for AIDS Research Developmental Grant Review Committee, and has served as an ad hoc member of the National Institute of Allergy and Infectious Diseases (NIAID), the Medical Research Council (MRC, UK), as well as an ad hoc member of similar committees in Netherlands, Austria, and Switzerland. Dr. Gallay has more than 85 peer-reviewed publications.

Overview
RelSci Relationships

78

Number of Boards

2

Contact Data
Trying to get in touch with Philippe Gallay? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Philippe Gallay likely has professional access to. A relationship does not necessarily indicate a personal connection.

Honorary Professor, Hepatology at University College London

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Hepion Pharmaceuticals, Inc.

Relationship likelihood: Strong

Senior Vice President-Technical Operations at Sierra Oncology, Inc.

Relationship likelihood: Strong

Clinical Professor-Medicine, Biostatistics & Epidemiology at UCSF School of Medicine

Relationship likelihood: Strong

Founder at CTI Clinical Trial & Consulting Services, Inc.

Relationship likelihood: Strong

Professional at McLaughlin-Rotman Centre for Global Health

Relationship likelihood: Strong

Professor, Head of the Liver Unit & Clinical Researcher, Ifi Institute at University of Hamburg

Relationship likelihood: Strong

Medical Director, Research Center at University of Southern California

Relationship likelihood: Strong

Head, Viral Hepatitis Team at Centre Léon Bérard Lyon et Rhône-Alpes

Relationship likelihood: Strong

Founder at Analgesic Solutions

Relationship likelihood: Strong

Paths to Philippe Gallay
Potential Connections via
Relationship Science
You
Philippe Gallay
Scientific Advisor at Abliva AB
Career History
Scientific Advisor
2017 - Current

Abliva AB engages in the research and development of pharmaceuticals that protect mitochondria from death post acute traumatic injury. Its projects include KL1333 AND NV354. The company was founded by Eskil Elmer on February 1, 2000 and is headquartered in Lund, Sweden.

Professor of Immunology, Department of Immunology & Microbiology
Current

The Scripps Research Institute (TSRI), one of the world's largest, private, non-profit research organizations, stands at the forefront of basic biomedical science, a vital segment of medical research that seeks to comprehend the most fundamental processes of life. Over the last decades, the institute has established a lengthy track record of major contributions to the betterment of health and the human condition. The institute — which is located on campuses in La Jolla, California, and Jupiter, Florida — has become internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, cardiovascular diseases, virology, and synthetic vaccine development. Particularly significant is the institute's study of the basic structure and design of biological molecules; in this arena TSRI is among a handful of the world's leading centers. The institute’s educational programs are also top-rate. The Kellogg School of Science and Technology is currently ranked among the best in the nation in its fields of biology and chemistry. Rather than isolating faculty members, students, and laboratories into separate and distinct disciplines, as is generally prescribed in universities, a cooperative, collaborative spirit is encouraged and embraced. While the level of scientific investigation is intense, the atmosphere is collegial, relaxed, and informal. Technicians, postdoctoral fellows, graduate students, and administrative support staff all are considered part of the team and are given the latitude and responsibility to accomplish their tasks so as to serve the best interests of science. The pursuit of scientific excellence is paramount and all efforts are directed toward that end. The bulk of the institute's funding is derived from the National Institutes of Health and other federal agencies. In today's environment of increasing competition for shrinking federal dollars, however, collaborative industrial partnerships with leading pharmaceutical companies provide additional funding in several areas key to the organization's research objectives. The Scripps Research Institute's adherence to the highest scientific standards, emphasis on a multidisciplinary approach to problem solving, participation in the perpetuation of knowledge through education, and continual pursuit of research excellence provide an unparalleled scientific environment.

Boards & Committees
Chair, Scientific Advisory Board
Current

Ciclofilin Pharmaceuticals, Inc. develops cyclophilin inhibitors for infectious, inflammatory and degenerative diseases. It offers Antiviral Drug Development, Liver Disease, Viral Co-Infection, Cyclophilin Inhibition, Macrocycle chemistry and Protein Folding. The company was founded in 2014 by Robert T. Foster and is headquartered in San Diego, PA.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Philippe Gallay. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Philippe Gallay's profile does not indicate a business or promotional relationship of any kind between RelSci and Philippe Gallay.